Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ADIAL PHARMACEUTICALS, INC. (ADIL)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues | 100.0% | | 100.0% | 100.0% | | | | |
| Cost of goods sold | 6.3% | | 0.0% | 0.0% | | | | |
| Gross profit | 93.7% | | 100.0% | 100.0% | | | | |
| Selling, general and administrative | | | | 177.1% | | | | |
| Research and development | 27.3% | | 21.0% | 26.5% | | | | |
| General and administrative | 66.4% | | 79.0% | | | | | |
| EBITDA | -4.1% | | -18.0% | -3.5% | | | | |
| Depreciation | | | 0.1% | 0.0% | | | | |
| EBITA | -4.1% | | -18.1% | -3.6% | | | | |
| Amortization of intangibles | | | 0.0% | 0.0% | | | | |
| EBIT | -4.1% | | -18.1% | -3.6% | | | | |
| Pre-tax income | 164.8% | | -18.8% | -73.3% | | | | |
| Income taxes | 95.8% | | 99.8% | 0.0% | | | | |
| Net income | -95.8% | | -99.8% | -73.3% | | | | |
|